Ukuyeka ukwelashwa kungabangela ukuba i-MS enzima ibuyele kwezinye
I-Tysabri (natalizumab) yisisetshenziswa esishintsha isifo esisetshenziselwa ukwelashwa kabusha kubantu abane- multiple sclerosis (MS) . Kuvimbela ikhono lamasosha omzimba ukuwela umkhawulo wegazi-ochotshozayo ohlukanisa ubuchopho nomgogodla kuwo wonke umzimba. Yilawa maseli angabangela umonakalo wezibilini njengoba bewahlupha ngokungahambisani nomshini wabo wokuzivikela (owaziwa ngokuthi i- myelin sheath ).
I-Tysabri ivunywe yi-US Food and Drug Administration (FDA) ukuze isetshenziswe ku-MS monotherapy (engeke ihlanganiswe nezinye izindlela zokwelapha) futhi iphathwe ngendlela yangaphakathi zonke izinsuku ezingu-28.
Izingozi Ezihlobene Nokusetshenziswa kwe-Tysabri
Ngesikhathi uTysabri ekhonjisiwe ukunciphisa ukuphindaphinda kubantu abane-MS ngamaphesenti angu-68 ashaya, akusikho ngaphandle kokukhathazeka kwayo. Ngo-2005, i-FDA yakhipha isixwayiso sebhokisi elimnyama eseluleka iziguli nodokotela ukuthi uTysabri wayephakathi kwabangu-2 000 abasebenzisi abangu-1 000 abhekana nokutheleleka kobuchopho obubulalayo obubizwa ngokuthi yi- progressive multifocal leukoencephalopathy (PML) .
Okunye okukhathazeka okuncane okuyiyona into eyaziwa ngokuthi i-rebound lapho ukuyeka noma ukuphazanyiswa kwalesi sidakamizwa kubangela ukubuya kwezimpawu ze- MS eziphindaphinda , kwezinye izimo zimbi nakakhulu uma ukwelashwa kuqalwa.
Ukuqonda Impumelelo Ebuyisiwe
Umthelela we-Tysabri wabonakala kuqala ngo-2007 lapho abaphenyi baseDashi behlola ukuhlolwa kwe- MRI yabantu ababebe bathatha iTysabri kodwa kwadingeka bayeke lapho isidakamizwa sisuswe okwesikhashana emakethe ngenxa yokukhathazeka kwe-PML.
Phakathi nale gap yezinyanga ezingu-15 zokwelapha, ososayensi bathola ukuthi isilinganiso senani lezilonda esisimweni sezinzwa zomphakathi seye sanda kusuka ku-3.43 ekuqaleni kokuqala ukwelashwa kuya ku-10.32 emva kokwelashwa kwavalwa.
Okumangalisa ukuthi, lesi siphumo asizange sibonakale sibi nakakhulu kubantu ababebekwe ukwelashwa isikhathi eside.
Eqinisweni, kwakungeyona into ehlukile. Ngokusho kocwaningo, labo abaye babhekana nezinkinga ezimbalwa zeTysabri babe nezilonda ezinhlanu ngaphezu kwalabo abaye belashwa isikhathi sonke sesifundo (cishe ama-36 infusions).
Ucwaningo olufanayo ngo-2014 lwesekela lezi zimangalo futhi laphetha ngokuthi ukuphazanyiswa kokwelashwa kwaxhunyaniswe nokwanda okuphindwe kabili engcupheni yokubuyela emuva. Ngokuphathelene nokuthi okwamanje kwakungenxa yokuthi ingxenye yesine yalaba bantu yayiphinde ibuyele emuva ngemva kokuyeka iTysabri kunangaphambi kokuqala ukwelashwa.
Lokho Okusitshelayo
Ososayensi abakwazi ngokuphelele ukuthi kungani lesi senzo esivukelayo senzekile. Okufanayo kuye kwaphawulwa kwezinye izidakamizwa ze-MS, kuhlanganise noGilenya (fingolimod) , futhi kukhona okungaqondakali okuncane okwenziwe ukuyivimbela.
Lokho esikwaziyo yilokhu: abantu abasengozini enkulu yilabo abathatha izinyanga ezimbalwa zeTysabri bese beyeka. Uma kunconywa ukwelashwa nge-Tysabri, wena njengesiguli kudingeka uzinike ekwelapheni bese unamathela kuso. Awukwazi ukuthatha amaholidi okudakamizwa okungaqondakali noma unqume ukuma uma futhi uzizwe ungcono.
Ukwelashwa ekugcineni kudinga ukuqondiswa ngumchwepheshe oqeqeshiwe ongakwazi ukucacisa ukuthi uma ngabe uTysabri engasadingeki yini.
> Imithombo:
> Fox, R .; I-Cree, et al. "Umsebenzi wesifo se-MS ku-REESTORE: isifundo sokuphazamiseka kokwelashwa kwe-natalizumab esingama-24." I-Neurology 2014; 82 (17): 1491-8.
> Sorensen, P .; UKoch-Henrikson, uH .; Petersen, T. et al. "Ukuphindaphindiwe noma ukuvuselelwa kwemitholampilo emuva kokuyeka ukwelashwa kwe-natalizumab kuma-MS asebenza kahle kakhulu." J Neurol . 2014; 261 (6): 1170-7.
> Vellinga, M .; I-Castelijns, i-J .; Barkhof, F. et al. "Ukwanda kwe-reblogged rebound ku-T2 umsebenzi we-lesional kwiziguli ze-MS eziphathwe nge-natalizumab." I-Neurology. 2008; 70 (13): 1150-1.